Preliminary report of tolvaptan treatment in japanese patients with heart failure

Hiroaki Semba; Koichiro Kinugawa; Norihiko Takeda; Taro Shiga; Go Nishimura; Tsukasa Inajima; Yuichi Uchino; Hiroshi Iwata; Eriko Hasumi; Hajime Abe; Yumiko Terada; Akihiko Yonenaga; Yasunobu Hirata; Ryozo Nagai

doi:10.1536/ihj.53.72

Preliminary report of tolvaptan treatment in japanese patients with heart failure

Hiroaki Semba, Koichiro Kinugawa^*, Norihiko Takeda, Taro Shiga, Go Nishimura, Tsukasa Inajima, Yuichi Uchino, Hiroshi Iwata, Eriko Hasumi, Hajime Abe, Yumiko Terada, Akihiko Yonenaga, Yasunobu Hirata, Ryozo Nagai

^*Corresponding author for this work

Internal Medicine （2）

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

While diuretic drugs are commonly used in patients with congestive heart failure, the efficacy of their long-term use still remains controversial. Recently, a new class of diuretics, vasopressin receptor 2 antagonists, has been launched, and tolvaptan is one such drug. We describe our initial experience with this novel agent. Tolvaptan is potentially useful for treatment of heart failure patients with fluid overload who are refractory to conventional diuretic therapies.

Original language	English
Pages (from-to)	72-74
Number of pages	3
Journal	International Heart Journal
Volume	53
Issue number	1
DOIs	https://doi.org/10.1536/ihj.53.72
State	Published - 2012

Keywords

Fluid overload
Heart failure
Tolvaptan
V2 antagonist

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1536/ihj.53.72

Cite this

@article{cc0af1a40eb646fb869ce26cb1700f40,

title = "Preliminary report of tolvaptan treatment in japanese patients with heart failure",

abstract = "While diuretic drugs are commonly used in patients with congestive heart failure, the efficacy of their long-term use still remains controversial. Recently, a new class of diuretics, vasopressin receptor 2 antagonists, has been launched, and tolvaptan is one such drug. We describe our initial experience with this novel agent. Tolvaptan is potentially useful for treatment of heart failure patients with fluid overload who are refractory to conventional diuretic therapies.",

keywords = "Fluid overload, Heart failure, Tolvaptan, V2 antagonist",

author = "Hiroaki Semba and Koichiro Kinugawa and Norihiko Takeda and Taro Shiga and Go Nishimura and Tsukasa Inajima and Yuichi Uchino and Hiroshi Iwata and Eriko Hasumi and Hajime Abe and Yumiko Terada and Akihiko Yonenaga and Yasunobu Hirata and Ryozo Nagai",

year = "2012",

doi = "10.1536/ihj.53.72",

language = "英語",

volume = "53",

pages = "72--74",

journal = "International Heart Journal",

issn = "1349-2365",

publisher = "International Heart Journal Association",

number = "1",

}

TY - JOUR

T1 - Preliminary report of tolvaptan treatment in japanese patients with heart failure

AU - Semba, Hiroaki

AU - Kinugawa, Koichiro

AU - Takeda, Norihiko

AU - Shiga, Taro

AU - Nishimura, Go

AU - Inajima, Tsukasa

AU - Uchino, Yuichi

AU - Iwata, Hiroshi

AU - Hasumi, Eriko

AU - Abe, Hajime

AU - Terada, Yumiko

AU - Yonenaga, Akihiko

AU - Hirata, Yasunobu

AU - Nagai, Ryozo

PY - 2012

Y1 - 2012

N2 - While diuretic drugs are commonly used in patients with congestive heart failure, the efficacy of their long-term use still remains controversial. Recently, a new class of diuretics, vasopressin receptor 2 antagonists, has been launched, and tolvaptan is one such drug. We describe our initial experience with this novel agent. Tolvaptan is potentially useful for treatment of heart failure patients with fluid overload who are refractory to conventional diuretic therapies.

AB - While diuretic drugs are commonly used in patients with congestive heart failure, the efficacy of their long-term use still remains controversial. Recently, a new class of diuretics, vasopressin receptor 2 antagonists, has been launched, and tolvaptan is one such drug. We describe our initial experience with this novel agent. Tolvaptan is potentially useful for treatment of heart failure patients with fluid overload who are refractory to conventional diuretic therapies.

KW - Fluid overload

KW - Heart failure

KW - Tolvaptan

KW - V2 antagonist

UR - http://www.scopus.com/inward/record.url?scp=84857811061&partnerID=8YFLogxK

U2 - 10.1536/ihj.53.72

DO - 10.1536/ihj.53.72

M3 - 学術論文

C2 - 22398679

AN - SCOPUS:84857811061

SN - 1349-2365

VL - 53

SP - 72

EP - 74

JO - International Heart Journal

JF - International Heart Journal

IS - 1

ER -

Preliminary report of tolvaptan treatment in japanese patients with heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this